Standout Papers

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interfer... 1998 2026 2007 2016 1.9k
  1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (1998)
    Thierry Poynard, Patrick Marcellin et al. The Lancet

Immediate Impact

7 by Nobel laureates 18 from Science/Nature 95 standout
Sub-graph 1 of 17

Citing Papers

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
2020 StandoutNature
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
1 intermediate paper

Works of Gerald Minuk being referenced

Fatty Infiltration of Liver in Hyperlipidemic Patients
2000
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
1998 Standout

Author Peers

Author Last Decade Papers Cites
Gerald Minuk 1947 1954 211 8 2.3k
Anuchit Chutaputti 2107 1919 103 29 2.5k
G. Giustina 2050 2082 128 39 2.5k
Marie–Pierre Ripault 2177 2184 143 33 2.4k
Chris Estes 2211 2330 99 24 2.6k
Susannah Cort 2475 2751 343 18 3.5k
Paul Neuwald 1644 1721 306 18 2.3k
David Sheridan 2202 2152 407 36 2.9k
Bart J. Veldt 2435 2369 120 41 2.9k
Vilma Sniukiene 1978 2258 231 39 2.5k
J. Moussalli 2292 2285 122 56 2.6k

All Works

Loading papers...

Rankless by CCL
2026